Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases

Erlotinib and pemetrexed have been approved for the second-line treatment of non-small cell lung cancer. Recent reports indicated that erlotinib and pemetrexed exerted synergistic effects against lung adenocarcinoma. The available treatment options for lung cancer with brain metastases (BM) are curr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: ZHANG, YALEI, YANG, HAIHONG, YANG, XINYUN, DENG, QIUHUA, ZHAO, MEILIN, XU, XIN, HE, JIANXING
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: D.A. Spandidos 2014
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3999131/
https://ncbi.nlm.nih.gov/pubmed/24772316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2014.256
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia